Sökning: L773:1471 2598 OR L773:1744 7682 >
GAD-alum (Diamyd) -...
GAD-alum (Diamyd) - a new concept for preservation of residual insulin secretion
-
- Ludvigsson, Johnny (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Pediatrik,Hälsouniversitetet,Barn- och ungdomskliniken i Linköping
-
(creator_code:org_t)
- 2010-03-15
- 2010
- Engelska.
-
Ingår i: EXPERT OPINION ON BIOLOGICAL THERAPY. - : Ashley Publications. - 1471-2598 .- 1744-7682. ; 10:5, s. 787-799
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Importance of the field: Type 1 diabetes is a common and very serious disease. There has been very active research going on for a long time aiming at preservation of the residual insulin secretion by some kind of intervention to stop the destructive autoimmune process. This review covers a new type of immune intervention using auto-antigen treatment. Areas covered in this review: Immune interventions in type 1 diabetes have been tried during the last 30 years, this review mentions some of them, but the main topic is the use of the auto-antigen glutamic acid decarboxylase ( GAD) to create tolerance to stop the autoimmune process. The clinical trials have been performed during the last 15 years and are all covered. What the reader will gain: This review will give the reader a picture of the research behind treatment with GAD as an immune intervention in type 1 diabetes. Take home message: The key finding so far is that treatment with Diamyd (R) has not only been shown to preserve residual beta cell function in type 1 diabetes, but this treatment may be the proof in humans of a new concept of treating and perhaps even preventing autoimmune diseases.
Nyckelord
- Diamyd
- GAD
- GADA
- immune intervention
- prevention
- type 1 diabetes
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas